dalteparin has been researched along with Fibrosis in 10 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 7.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 3.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z | 1 |
| Li, S | 1 |
| Zhao, J | 1 |
| Li, J | 1 |
| Gao, Y | 1 |
| Spronk, HM | 1 |
| De Jong, AM | 1 |
| Verheule, S | 1 |
| De Boer, HC | 1 |
| Maass, AH | 1 |
| Lau, DH | 1 |
| Rienstra, M | 1 |
| van Hunnik, A | 1 |
| Kuiper, M | 1 |
| Lumeij, S | 1 |
| Zeemering, S | 1 |
| Linz, D | 1 |
| Kamphuisen, PW | 1 |
| Ten Cate, H | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| van Zonneveld, AJ | 1 |
| Schotten, U | 1 |
| Diaz, JA | 1 |
| Wrobleski, SK | 2 |
| Alvarado, CM | 1 |
| Hawley, AE | 2 |
| Doornbos, NK | 1 |
| Lester, PA | 1 |
| Lowe, SE | 1 |
| Gabriel, JE | 1 |
| Roelofs, KJ | 1 |
| Henke, PK | 3 |
| Schaub, RG | 3 |
| Wakefield, TW | 3 |
| Myers, DD | 3 |
| Ayata, M | 1 |
| Kaptan, Z | 1 |
| Uzunkulaoğlu, H | 1 |
| Akyıldız, İ | 1 |
| Tüzüner, A | 1 |
| Ünverdi, H | 1 |
| Karadaş, H | 1 |
| Sood, V | 1 |
| Luke, C | 1 |
| Miller, E | 1 |
| Mitsuya, M | 1 |
| Upchurch, GR | 1 |
| Emami, MJ | 1 |
| Namazi, H | 1 |
| Vosoughi, AR | 1 |
| Nezhad, ST | 1 |
| Oryan, A | 1 |
| Mozaffarian, K | 1 |
| Bedard, PW | 1 |
| Kaila, N | 1 |
| Shaw, G | 1 |
| Meier, TR | 2 |
| Assy, N | 1 |
| Hussein, O | 1 |
| Khalil, A | 1 |
| Luder, A | 1 |
| Szvalb, S | 1 |
| Paizi, M | 1 |
| Spira, G | 1 |
| Baxi, S | 1 |
| Crandall, DL | 1 |
| Wrobleski, S | 1 |
| Hawley, A | 1 |
| Farris, D | 1 |
| Elokdah, H | 1 |
| Sigler, R | 1 |
| Wakefield, T | 1 |
| Myers, D | 1 |
| Abe, W | 1 |
| Ikejima, K | 1 |
| Lang, T | 1 |
| Okumura, K | 1 |
| Enomoto, N | 1 |
| Kitamura, T | 1 |
| Takei, Y | 1 |
| Sato, N | 1 |
1 trial available for dalteparin and Fibrosis
| Article | Year |
|---|---|
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.
Topics: Albumins; Anticoagulants; Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Hum | 2023 |
9 other studies available for dalteparin and Fibrosis
| Article | Year |
|---|---|
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; F | 2017 |
P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.
Topics: Animals; Aptamers, Nucleotide; Blood Coagulation; Collagen; Disease Models, Animal; Enoxaparin; Fibr | 2015 |
Effect of Enoxaparin Sodium on Experimentally-Induced Myringosclerosis in Rats.
Topics: Animals; Anticoagulants; Calcinosis; Disease Models, Animal; Enoxaparin; Fibrosis; Hyalin; Hyperemia | 2015 |
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.
Topics: Animals; Disease Models, Animal; Doxycycline; Elasticity; Enoxaparin; Fibrin Fibrinogen Degradation | 2010 |
Can enoxaparin prevent arthrofibrosis?
Topics: Animals; Enoxaparin; Fibrinolytic Agents; Fibrosis; Joint Diseases; Knee Joint; Male; Orthopedic Pro | 2012 |
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.
Topics: Animals; Anticoagulants; Constriction, Pathologic; Disease Models, Animal; Enoxaparin; Fibrosis; Hyd | 2006 |
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
Topics: Animals; Aspartate Aminotransferases; Aspirin; Bilirubin; Disease Progression; Enoxaparin; Fibrinoly | 2007 |
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxaparin; Fibrosis; Indoleaceti | 2008 |
Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.
Topics: Actins; Animals; Carbon Tetrachloride; Collagen Type I; Collagen Type I, alpha 1 Chain; Dalteparin; | 2007 |